Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.
Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. Br J Clin Pharmacol. 2020 09; 86(9):1769-1777.